
Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

